News Focus
News Focus
Replies to #78272 on Biotech Values
icon url

jbog

05/21/09 2:55 PM

#78274 RE: genisi #78272

All doses of once-daily QAB149 met their main target in Phase III trials for treating chronic obstructive pulmonary disease (COPD),

There's not much available in the way of treating COPD.
icon url

DewDiligence

05/21/09 5:19 PM

#78281 RE: genisi #78272

NVS has a number of drugs with big-selling potential in the late-stage pipeline. They will need all of them to contribute to make up for Diovan’s going off-patent.